IVIG Revenue Growth

The Q2 2026 earnings call emphasized that revenue growth is largely driven by U.S. demand for intravenous immunoglobulin (IVIG). Grifols has a strong foothold in the rapidly expanding subcutaneous IVIG market, which offers clinical advantages over traditional IVIG. Confidence also extends to the SPARTA AATD trial, aiming to demonstrate efficacy and safety of the company’s AAT therapy. A restructuring plan is in place to improve operational efficiency and cut costs. Key risks highlighted were competition from other IVIG players, notably CSL Limited; regulatory uncertainties surrounding the SPARTA AATD trial; and the impact of pricing pressures and reimbursement changes on revenue.